search
Back to results

Obesity in Children and Adolescents: Associated Risks and Early Intervention (OCA)

Primary Purpose

Obesity

Status
Completed
Phase
Phase 3
Locations
Lithuania
Study Type
Interventional
Intervention
Metformin
Sponsored by
Lithuanian University of Health Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring weight, body mass index, lipid profile, glucose profile

Eligibility Criteria

10 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 10-17 yrs;
  • Weight > 85th percentile for age and gender (by IOTF);
  • Living in Kaunas and its region;
  • No obvious chronic diseases;
  • Not on steroid or other long-term treatment;
  • Informed consent of the patient and parents (official caregivers);

Exclusion Criteria:

  • Age less than 10 or above 17 yrs;
  • Diagnosis of type 1 diabetes;
  • Chronic illness that may affect physical activity and metabolic profile;
  • Insulin treatment;
  • Steroid treatment;
  • Planning to move from Kaunas or its region in the period of 1 year;
  • Protocol refused by the patient or his parents;

Sites / Locations

  • Rasa Verkauskiene

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

Experimental

Experimental

No Intervention

Arm Label

Control without Metformin

Control with Metformin

Intervention with Metformin

Intervention without Metformin

Arm Description

Conventional management of obesity including basic instructions on diet and physical activity

Conventional management of obesity including basic instructions on diet and physical activity plus Metformin treatment

Intensive physical activity course twice per week and monthly diet control by dietitian plus Metformin treatment.

Intensive physical activity course twice per week and monthly diet control by dietitian

Outcomes

Primary Outcome Measures

Body mass index changes
decrease in body mass index

Secondary Outcome Measures

Glucose homeostasis
Insulin sensitivity increase, homeostasis model assessment (HOMA-IR) decrease, insulin and glucose concentrations normalisation
Lipid profile
Lipid profile normalisation
Metabolic syndrome
Metabolic syndrome prevalence and risks decrease
Hepatosteatosis
Hepatosteatosis prevalence decrease and liver function improvement, hepatic enzymes normalisation
Polycystic ovary syndrome (PCOS) and hyperandrogenism in females
PCOS clinical symptoms regression, menstrual cycle normalisation, hirsutism, androgens levels decreasing and estrogen, sex hormone-binding globulin (SHBG) levels increasing

Full Information

First Posted
July 30, 2012
Last Updated
March 2, 2016
Sponsor
Lithuanian University of Health Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT01677923
Brief Title
Obesity in Children and Adolescents: Associated Risks and Early Intervention
Acronym
OCA
Official Title
Phase 3: Effect of Diet, Physical Activity and Insulin Sensitizer Metformin on Obesity and Associated Risks in Children and Adolescents.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Lithuanian University of Health Sciences

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators hypothesize that Metformin decreases weight, normalizes lipid profile and increases insulin sensitivity; the study team hope to get better effect of weight decrease and metabolic processes repair in the intensive treatment group with intervention of physical activity, diet correction and Metformin use.
Detailed Description
During the first visit, study participants would follow the clinical investigation (anthropometry, physical examination, blood tests (hormonal and biochemical state), bioimpedance, ultrasound evaluation) and be attributed into 4 groups (matched for age, gender, pubertal stage and BMI), 100 subjects in each group. st group - control: during the first visit patients get standardized information on healthy lifestyle, diet and exercise. Next visit (control) will be scheduled for the clinical and laboratory evaluation after 12 months of intervention. nd group - intensive diet and physical activity group: Children will be seen by a dietician once a month for diet re-evaluation; physical therapist, who will give physical activity course twice a week (1 h each). pediatric endocrinologist every 3 months. Clinical and laboratory evaluation after 12 months of intervention. rd group - intensive diet and physical activity group plus insulin sensitization: Metformin will be prescribed for this group of study children in the doses of 1000 mg/day Children will be seen by a dietician once a month for diet re-evaluation; physical therapist, who will give physical activity course twice a week (1 h each); pediatric endocrinologist every 3 month. Clinical and laboratory evaluation after 12 months of intervention. th group- insulin sensitization without intensive diet and physical activity. Metformin will be prescribed in the doses of 1000 mg/day after standardized information on healthy lifestyle, diet and exercise during the first visit only. This group of children will be seen by pediatric endocrinologist every 3 months. Intervention duration - 12 months. In the case of Metformin intolerance, children will continue the study in 2nd group. Clinical and laboratory evaluation after 12 months of intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
weight, body mass index, lipid profile, glucose profile

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
182 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control without Metformin
Arm Type
No Intervention
Arm Description
Conventional management of obesity including basic instructions on diet and physical activity
Arm Title
Control with Metformin
Arm Type
Experimental
Arm Description
Conventional management of obesity including basic instructions on diet and physical activity plus Metformin treatment
Arm Title
Intervention with Metformin
Arm Type
Experimental
Arm Description
Intensive physical activity course twice per week and monthly diet control by dietitian plus Metformin treatment.
Arm Title
Intervention without Metformin
Arm Type
No Intervention
Arm Description
Intensive physical activity course twice per week and monthly diet control by dietitian
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
Metforal
Intervention Description
Metformin 500 mg BID for 12 months
Primary Outcome Measure Information:
Title
Body mass index changes
Description
decrease in body mass index
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Glucose homeostasis
Description
Insulin sensitivity increase, homeostasis model assessment (HOMA-IR) decrease, insulin and glucose concentrations normalisation
Time Frame
12 month
Title
Lipid profile
Description
Lipid profile normalisation
Time Frame
12 months
Title
Metabolic syndrome
Description
Metabolic syndrome prevalence and risks decrease
Time Frame
12 months
Title
Hepatosteatosis
Description
Hepatosteatosis prevalence decrease and liver function improvement, hepatic enzymes normalisation
Time Frame
12 months
Title
Polycystic ovary syndrome (PCOS) and hyperandrogenism in females
Description
PCOS clinical symptoms regression, menstrual cycle normalisation, hirsutism, androgens levels decreasing and estrogen, sex hormone-binding globulin (SHBG) levels increasing
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
safety
Description
how many patients will have adverse events and withdraw the Metformin due to their intolerance or clinical / biochemical relapse
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 10-17 yrs; Weight > 85th percentile for age and gender (by IOTF); Living in Kaunas and its region; No obvious chronic diseases; Not on steroid or other long-term treatment; Informed consent of the patient and parents (official caregivers); Exclusion Criteria: Age less than 10 or above 17 yrs; Diagnosis of type 1 diabetes; Chronic illness that may affect physical activity and metabolic profile; Insulin treatment; Steroid treatment; Planning to move from Kaunas or its region in the period of 1 year; Protocol refused by the patient or his parents;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rasa Verkauskiene, Professor
Organizational Affiliation
Lithuanian University of Health Sciences Hospital, Endocrinology Unit
Official's Role
Study Chair
Facility Information:
Facility Name
Rasa Verkauskiene
City
Kaunas
State/Province
Eiveniu str. 2
ZIP/Postal Code
LT50009
Country
Lithuania

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
Study results are in progress with statistical analysis

Learn more about this trial

Obesity in Children and Adolescents: Associated Risks and Early Intervention

We'll reach out to this number within 24 hrs